How much weight have people reported losing on GLP1?

Across the internet, people are reporting and talking about losing weight with GLP1 Receptor Agonist drugs:

• Semaglutide (Ozempic, WeGovy, Rybelsus)
• Tirzepatide (Mounjaro, Zepbound)
• Exenatide (Byetta)
• Liraglutide (Victoza, Saxenda)

What people are saying around the internet

Reddit is a common place to find people chatting about their experiences on GLP1:

While these aren't peer reviewed, researched facts, reports by regular people are still worth considering, so we've extracted a few here:

• Redditor Swimming-Vehicle8104 (35 yrs old) lost 18% (260 lbs -> 212 lbs), after being on Wegovy for 7 months (28 weeks)
• Redditor Adventurous_Sea5313 (60 yrs old) lost 6.4% (250 lbs -> 234 lbs) after being on Semaglutide for 2 months (8 weeks).
• Redditor marylss (46 yrs old) (46 yrs old) lost 17% (253 lbs -> 191 lbs) after being on Semaglutide for 34 weeks.
• Redditor autumnandscott (47 yrs old) lost 23.1% (182 lbs -> 140 lbs) after 6 months (24 weeks) on Semaglutide.
• Redditor Powerful-Parking1907 (27 yrs old) lost 9.6% (167 lbs -> 151 lbs), after 6 weeks on Semaglutide.

These are some pretty impressive numbers, often with people citing no exercise!

What does the research say?

At this point, all the major known GLP1 Receptor Agonist compounds have had scientific studies and trial performed (usually funded in some way by the company selling the drug), so we can easily look at the research.

While the specifics of the studies differ (ex. time people were taking the drugs, makeup of the participants, etc), there are some common threads.

Semaglutide (Ozempic, Wegovy, Rybelsus)

The STEP1 Trials are a great place to start for Semaglutide based drugs. The Step1 Trials found that weight change at week 68 was −14.9% with 2.4-mg semaglutide, as compared with −2.4% with placebo (estimated treatment difference, −12.4 percentage points, with a high confidence interval.

This means that Semaglutide contributed to roughly 12% percentage points of weight loss over the period.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a common and growing subset of the GLP1 drugs, Mounjaro being quite recognizable/mentioned in public.

The SURMOUNT-1 Trial is one of the most prominent trials done for Tirzepatide, and it tested various dosages, so we have some more data to compare. In this case the period measured was 72 weeks (compared to semaglutide's 68):

• 5mg Tirzepatide caused average ~12% weight loss (15% minus placebo 3.1%)
• 10mg Tirzepatide caused average ~16.5% weight loss (19.5% minus placebo 3.1%)
• 15mg Tirzepatide caused average 17.9% weight loss (20.9% minus placebo 3.1%)

Liraglutide (Victoza, Saxenda)

Liraglutide, similar to the other compounds has also had trials performed, so we can look at the SCALE trial.

The SCALE trial found that after 56 weeks, participants on Liraglutide lost an average of 8% of their body weight, whereas participants given the placebo lost 2.6%. This means Liraglutide contributed to roughly 5.4% of the average weight loss.

📬 Get the latest GLP1 news straight to your inbox